The American Academy of Dermatology has developed an up-to-date national Burden of Skin Disease Report on the impact of skin disease on patients and on the US population. In this second of 3 manuscripts, data are presented on specific health care dimensions that contribute to the overall burden of skin disease. Through the use of data derived from medical claims in 2013 for 24 skin disease categories, these results indicate that skin disease health care is delivered most frequently to the aging US population, who are afflicted with more skin diseases than other age groups. Furthermore, the overall cost of skin disease is highest within the commercially insured population, and skin disease treatment primarily occurs in the outpatient setting. Dermatologists provided approximately 30% of office visit care and performed nearly 50% of cutaneous surgeries. These findings serve as a critical foundation for future discussions on the clinical importance of skin disease and the value of dermatologic care across the population. ( J Am Acad Dermatol 2017;76:1151-60.)
S
kin disease affects millions of people worldwide and is a leading cause of global disease burden. 1 The past decade has brought therapeutic innovations to medicine but also many changes to the delivery of health care. [2] [3] [4] With finite resources available for research, clinical care, and public health initiatives, it is imperative to accurately quantify the overall burden of skin disease for the US population.
The last national Burden of Skin Disease (BSD) Report was published over 10 years ago. 5 The American Academy of Dermatology (AAD) has developed an up-to-date BSD Report to provide a comprehensive assessment of the prevalence and economic burden of 24 skin disease categories through the use of 2013 medical claims data tabulation. 6 This report estimates that 85 million Americans were seen by a physician for at least 1 skin disease in 2013. This led to an associated direct health care cost of nearly $75 billion and resulted in $11 billion in lost productivity. 7 In this second of 3 manuscripts, these data have been further analyzed related to patient age, skin disease, insurance status, and other health care factors. These data yield further insights to inform discussions on dermatologic health care access, treatment selection, care coordination, and policy decisions.
METHODS
In 2014, the AAD appointed a BSD Work Group* to develop a current BSD report. Milliman (New York, NY) was selected to work with the BSD Work Group. Detailed methodology can be found in the AAD BSD Report. 6 US population data and prevalence measurement methodology, identification and categorization of skin diseases, and definitions of health care cost categories have been described in detail in the first manuscript of this series. 7 They are briefly summarized below.
Skin disease category classification
Twenty-four skin disease categories were identified for inclusion in this report and were assigned corresponding skin-related 2013 International Classification of Disease, Ninth Edition, diagnosis codes. The identification and assignment of skin conditions and International Classification of Disease, Ninth Edition, codes followed a set of key principles.
US population by age and insurance status
Medical Expenditure Panel Survey data were used to estimate the US 2013 population by age and insurance status. Specifically, the participants' primary payer as of July 1, 2013 As described in the first manuscript, a set of data selection rules for each data source was established to ensure representative and quality data. 7 
Prevalence measurement methodology
Prevalence in this report refers to the portion of the population having at least 1 of the 24 skin disease categories recorded on a health insurance claim during 2013. A skin disease diagnosis during 2013 may reflect both newly diagnosed skin disease and chronic skin disease requiring ongoing treatment. Prevalence, therefore, excludes people with a skin disease who did not file insurance claims in 2013, regardless of reason. To estimate the number of individuals diagnosed with skin disease in 2013, the specific prevalence for each skin disease category was converted to the number of individuals on the basis of the total population for each insured status. The prevalence for a specific skin disease category was compared on the basis of age groups by averaging the relative prevalence ratio between successive age groups.
Medical cost tabulation and dimensions
Medical costs associated with skin disease were determined through the use of diagnosis codes, procedure codes, national drug codes, and physician specialty codes to identify skin diseaseeassociated claims. When a claim had diagnoses for skin and nonskin diseases, costs were divided among the conditions such that only the skin disease portion
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was included in tabulations. Claims data were tabulated as inpatient, outpatient therapies, outpatient surgeries/procedures, other dermatology procedures, and office visits. The complete list of surgical procedures included in the analysis is provided in Supplemental Table I (available at http:// www.jaad.org). 6 On the basis of established Current Procedural Terminology categories, phototherapy, photochemotherapy, photodynamic therapy, and targeted phototherapy were not considered surgery and therefore not included in the analysis. Whereas the classification used was appropriate to provide a consistent approach across all skin diseases, it is not intended to represent a standard with regard to defining codes as ''surgeries/procedures'' versus ''other'' for payment policy or legislative purposes. For the uninsured population, commercial tabulated costs were used and the uninsured-to-commercial cost ratio by type of service was applied. Services and costs for the 24 skin disease categories were assigned to the first skin diagnosis on the claim.
To calculate the cost per individual with diagnosed skin disease, the total cost for each skin disease was divided by the number of individuals diagnosed with the skin disease. This calculation was performed for the total population and by insurance status. Note that 1 individual may have more than 1 diagnosed skin disease.
Prescription drug tabulation dimensions
Through the use of the claims datasets, prescription drug claims in 1 (or more) of the following categories were identified: Costs were tabulated by means of insurance status, type of drug, and specialty status.
RESULTS

Impact of age and insurance status on skin disease diagnosis
The demographics of each insured population has been shown previously, 7 with Medicaid predominantly patients age 0 to 17 years and Medicare patients predominantly age $65 years. The prevalence of skin disease was highest among patients with Medicare (47.8%) compared with those who had commercial insurance (22.5%), were on Medicaid (24.6%), and were uninsured (23.6%) (Fig 1, A) . Patients with Medicaid had a higher prevalence of wounds and burns, contact dermatitis, and cutaneous infections relative to all other skin diseases (Fig 1, B) . Several conditions were most prevalent in the Medicare population, including noncancerous skin growths, y viral/fungal diseases, actinic damage, and cutaneous infections. Furthermore, the Medicare population also had a high probability of a concurrent skin disease diagnosis (Fig 1, C ) .
The prevalence of skin disease generally increased with age. Sixteen of the 24 skin diseases had a noted increase from age 0 to $65 years; these are grouped in ''high'' or ''moderate increase'' in Fig  2, A. Eight skin diseases had prevalence that was relatively constant for all age groups, with a notable and expected exception of acne, which showed a decrease. Nonmelanoma skin cancer, ulcers, and actinic damage had the highest relative change in prevalence over time, increasing by 4-to [14-fold with age (Fig 2, B) .
Direct medical cost of skin disease by insurer
The medical cost for the 24 skin disease categories was nearly $46 billion in 2013. 7 The medical cost for each skin disease varied widely, ranging from more than $8 billion for cutaneous lymphoma to $49 million for vitiligo (Fig  3) . Total medical costs for the treatment of ulcers, cutaneous infections, and nonmelanoma skin cancer were highest in the Medicare population.
Overall, the top 10 skin diseases, on the basis of medical cost, generally correlated with the most prevalent skin disease categories within each insurance status, with some exceptions (Fig 4) . For example, melanoma and connective tissue diseases represent a combined prevalence of 0.48% in the commercial population, yet result in 7.3% ($1.4 billion) of the total medical cost for this group. For each insurance status, the 10 skin diseases with the highest economic burden accounted for [80% of the total medical cost in each group.
Cost per person diagnosed with skin disease
Across the total insured population, the skin diseases with the highest pereaffected person costs were cutaneous lymphoma ($2403 to $4517), ulcers ($1317 to $1979), melanoma ($991 to $1923), nonmelanoma skin cancer ($1154 to $1311), and connective tissue diseases ($952 to $1703) (Fig 5) .
y This skin disease category is clinically broad in nature. In practice, these growths may be biopsied to rule out skin cancer or other underlying skin disease pathology. The final pathology results for some are benign (noncancerous). US population with skin disease by insurance status. A, The stacked column graph represents the relative percentage of the US population with skin disease (pink), compared to those without skin disease (gray) for each insurance status. The actual number of individuals (in thousands) is indicated inside the bar. B, The table lists the 24 skin disease categories in alphabetical order, and indicates the prevalence of population with a specific skin disease (in percentage) for each insurance status (commercial, Medicare, Medicaid, and uninsured). The colored cells indicate a ''heat map'' of prevalence, ranging from highest prevalence (dark red) to lowest prevalence (dark blue) for each insurance status. C, The bubble graphs plot the probability of a Medicare-insured individual diagnosed with melanoma, actinic damage, noncancerous skin growths, ulcers, or congenital abnormalities of having another skin disease. The relative probability is indicated by the size of the bubble, with the actual probability percentage in each label. The y axis plots the percentage prevalence of skin disease in the Medicare population and the center of each bubble corresponds to the disease-specific prevalence. For 21 of the 24 skin diseases, approximately 75% of the medical costs attributable to skin disease were for outpatient services, whereas 25% were for inpatient services (data not shown). The top 10 skin disease categories associated with high inpatient costs for each insurance status are shown in Fig  6. Accurate data for the uninsured population are lacking; therefore, no information can be presented for this group. Across the 24 skin disease categories, total aggregate medical costs for the commercially insured often exceeded those of the other insurance groups.
Top prescription drugs for skin disease by insurer
The majority (82.5%) of total prescription drug costs for skin disease across insurance statuses were for nonspecialty drugs (typically nonbiologic, longestablished drugs), 10 and 17.5% were for specialty drugs (typically biologic and/or injectable drugs) 10 ( Fig 7, A) . Total prescription drug costs for skin disease was highest in the commercially insured population (Fig 7, A, upper panel) ; however, the pereMedicare-insured person cost for prescription drugs z was higher than for other insured populations (Fig 7, A, lower panel) because of a higher skin disease prevalence in this population.
Prescriptions for 10 skin disease drugs accounted for approximately 40% of total prescription drug costs across all insurance statuses (Fig 7, B) . These z Skin vaccines may be billed as either a medical or a prescription drug benefit; when the costs for these benefits were added to the total per person cost, the final costs were $53.34 for commercially insured individuals, $79.53 for Medicare enrollees, and $26.15 for Medicaid participants.
top 10 prescription drugs varied by insurance status but included drugs used primarily for the treatment of psoriasis, infections, acne, and rosacea.
Dermatologist provision of care for skin disease
The percentage of office visits for skin disease with dermatologists was 35.4% for the commercially insured population, 42.6% for Medicare patients, and 17.4% for Medicaid recipients (Fig 8, A) . The percentage of surgical procedures for skin disease performed by dermatologists was 53.7% for the commercially insured population, 53.0% for those on Medicare, and 31.5% for Medicaid patients (Fig 8,  B) . Vitiligo, psoriasis, rosacea, and cutaneous lymphoma were predominantly seen by dermatologists for all insurance statuses (Fig 8, C ) . Furthermore, for Medicare patients and the commercially insured, actinic damage, acne, and nonmelanoma skin cancer were also among the top 10 skin disease categories seen by dermatologists.
DISCUSSION
In 2013, nearly 85 million Americans were diagnosed with and treated for skin disease. 7 The economic burden to the US society is affected by the prevalence of specific skin diseases, patient age, and insurance status. These results indicate that skin disease is a lifelong health care concern and affects individuals of all ages. Furthermore, most skin diseases increase in prevalence over a lifetime, resulting in nearly 50% of the Medicare population having at least 1 skin disease and often concurrent skin disease(s). With estimates that by 2030 the $65 years of age US population will grow by 30 million and continue to increase through 2050, 11 the burden of skin disease is likely to increase substantially.
The pereaffected-person per-year medical cost of treating a diagnosed skin disease showed great variability, ranging from less than $100 (seborrheic dermatitis) to more than $4500 (cutaneous lymphoma), depending on the disease and insurance status. Overall, the aggregate total medical cost of those commercially insured was higher compared with the costs of Medicare and Medicaid populations, although Medicare skin disease patients tended to have higher inpatient and prescription drug costs.
These findings also show that dermatologists were seen by 1 in every 3 people diagnosed with skin disease in 2013. In addition, dermatologists provided approximately 50% of surgical care for the treatment of skin disease. These results reinforce the role of these specialists in diagnosing and treating a vast array of skin diseases, many of them of frequent concern to patients, particularly those in the Medicare population. [12] [13] [14] Among Medicaid patients, there was a smaller percentage of visits to dermatologists compared with patients from the other 2 insurance statuses. This difference may be a reflection of the younger age of Medicaid patients, supported by the finding that the top 10 medications prescribed to this group are mostly for treatment of infections or dermatitis (Fig 7,  B) . A possible explanation could be that many were probably cared for by pediatricians for some skin diseases and only referred to dermatologists for further evaluation and treatment of lesions or other dermatologic conditions. Within each insured population, the 10 skin diseases with the highest economic burden generally correlated with the most prevalent skin disease categories, but this list also included skin diseases with lower prevalence such as cutaneous lymphoma, melanoma, and nonmelanoma skin cancer in the commercially insured and Medicaidinsured populations. Collectively, the top 10 most common skin diseases represented [80% of the total medical cost for each insured population. Additionally, the 10 most commonly prescribed drugs that were based on insurance status accounted for 40% of the total health care dollars spent on prescription drugs. These drugs are primarily used to treat psoriasis, acne, and cutaneous infections.
Skin disease is a significant and serious health consideration for patients, physicians, and payers. As the US population and health care systems continue to evolve, 15 it is critical to develop strategies that ensure effective access to dermatologic treatment in outpatient and inpatient settings across the insurance coverage spectrum, appropriate care coordination and referral to specialists, and resources to support patient self-care when appropriate. We also thank any others not listed here who contributed to the development and success of this report. 
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